Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SC10914 Monotherapy for gBRCA1/2 Mutation Advanced Ovarian Cancer Patients With at Least 2 Prior Lines of Chemotherapy: a Single Arm, Open Label, Multicenter Clinical Trial

NCT04556539 is registered in ClinicalTrials.gov with Jiangxi Qingfeng Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT04556539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04556539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SC10914 Monotherapy for gBRCA1/2 Mutation Advanced Ovarian Cancer Patients With at Least 2 Prior Lines of Chemotherapy: a Single Arm, Open Label, Multicenter Clinical Trial
Lead sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
December 15, 2020
Completion date
December 31, 2022
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ovarian cancer